The growing epidemic of obesity and overweight is a major cause of premature mortality, chronic morbidity, and increased healthcare cost. Although lifestyle modification is the first-line treatment recommended for obesity. Once lifestyle management fails, one need to switch to medication. Two such anti-obesity medicine are discussed in this article.
A proper decision out of lifestyle management, medication, and bariatric surgery is important in obesity management. All standard guidelines suggest considering adjunctive drug treatment in patients with a body mass index of 30 kg/m2 or more or 27 to 29.9 kg/m2 with medically complicated obesity. Use of antiobesity drugs is likely to increase along with the prevalence and incidence of obesity and with the development of newer agents. Orlistat, a gastrointestinal lipase inhibitor, and rimonabant, an endocannabinoid receptor antagonist, are…
